유방암 환자에서 적정 감시림프절의 개수: 방사성 동위원소를 이용한 1,026예 감시림프절 생검의 경험 = Optimal Sampling Number of Sentinel Lymph Nodes in Invasive Breast Cancer: Results of 1,026 Sentinel Lymph Node Biopsies Done by Radioisotope

다국어 초록 (Multilingual Abstract)

Purpose: For isotope mapping, many authors have defined the sentinel lymph node (SLN) as the one containing isotope counts higher than the axillary background. However, no study has sought to define an optimal guideline, and the number of SLNs needed for precise detection of metastatic SLNs is still a subject of debate. Accordingly, we set out to determine the optimal sampling number of SLNs. Methods: Between January 2005 and December 2008, we enrolled 1,026 patients with primary invasive breast cancer. These patients had received sentinel lymph node biopsy (SLNB) using radioisotopes at Yeungnam University Hospital. During SLNB, ex vivo isotope counts were measured for each SLN.And, the number and metastatic status of harvested SLNs were investigated. We defined SLNs as lymph nodes that show an isotope count ≥10 times that of the axillary background.Each SLN was labeled as S1 (highest isotope count),S2 (second highest), or S3 and so on, in descending isotopecount-order. If an SLN was positive for metastasis, completion axillary lymph node dissection was performed. Results: The mean age of patients was 48.9 years (ranges, 22-83 years). The mean number of removed SLNs was 2.8 (ranges, 1-11). Of the 1,026 patients enrolled, 311 (30.3%) had SLN metastasis: S1 was positive (S1+) in 258 patients (82.9%), S2 was positive (S1-, S2+) in 40 patients (12.3%), and S3 was positive (S1-, S2-, S3+) in 13 patients (3.9%). There was no metastasis in SLNs defined as S4, S5 and so on. The average number of sampling SLNs until detecting metastasis in S1, S2, and S3 was 1.24 (1-4), 2.45 (2-4), and 3.46 (3-5). Conclusion: During SLNB done using radioisotopes, for accurate axillary lymph node staging, up to the 3rd isotope-count-order of SLNs should be removed. The average number of SLNs needed for detecting metastasis in S3 is four.

참고문헌 (Reference)

1 구본용, "유방암의 감시림프절 생검에서 적절한 위음성률을 확보하기 위해 필요한 림프절 개수" 한국유방암학회 12 (12): 100-105, 2009

2 백창석, "유방암에 있어서 감마선량에 따른 감시림프절의 구분" 대한외과학회 65 (65): 3-3, 2003

3 Nieweg OE, "What is a sentinel node and what is a false-negative sentinel node" 11 (11): 169S-173S, 2004

4 Krag D, "The sentinel node in breast cancer: a multicenter validation study" 339 : 941-946, 1998

5 Ollila DW, "The role of intraoperative lymphatic mapping and sentinel lymphadenectomy in the management of patients with breast cancer" 32 : 349-364, 1999

6 Dabbs DJ, "The optimal number of sentinel lymph nodes for focused pathologic examination" 10 : 186-189, 2004

7 McCarter MD, "The breast cancer patient with multiple sentinel nodes: when to stop" 192 : 692-697, 2001

8 Morton DL, "Technical details of intraoperative lymphatic mapping for early stage melanoma" 127 : 392-399, 1992

9 McMasters KM, "Sentinel-lymph-node biopsy for breast cancer: not yet the standard of care" 339 : 990-995, 1998

10 Schrenk P, "Sentinel node biopsy for breast cancer: does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node" 80 : 130-136, 2002

11 Cody HS 3rd, "Sentinel lymph node mapping in breast cancer" 13 : 25-34, 1999

12 Woznick A, "Sentinel lymph node dissection for breast cancer: how many nodes are enough and which technique is optimal" 191 : 330-333, 2006

13 Borgstein PJ, "Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection" 186 : 275-283, 1998

14 McMasters KM, "Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used" 18 : 2560-2566, 2000

15 Veronesi U, "Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series" 91 : 368-373, 1999

16 Keskek M, "Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer" 36 : 1047-1052, 2006

17 Kjaergaard J, "Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer" 72 : 365-367, 1985

18 McLaughlin SA, "Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements" 26 : 5213-5219, 2008

19 Fleissig A, "Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer" 95 : 279-293, 2006

20 Krag DN, "Minimal-access surgery for staging of malignant melanoma" 130 : 654-658, 1995

21 Cox CE, "Lymphatic mapping in the treatment of breast cancer" 12 : 1283-1292, 1998

22 Hill AD, "Lessons learned from 500 cases of lymphatic mapping for breast cancer" 229 : 528-535, 1999

23 Yi M, "How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer" 113 : 30-37, 2008

24 Martin RC, "Highest isotope count does not predict sentinel node positivity in all breast cancer patients" 8 : 592-597, 2001

25 Cox CE, "Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer" 227 : 645-651, 1998

26 Nieweg OE, "False-negative sentinel node biopsy" 16 : 2089-2091, 2009

27 Hoar FJ, "A prospective study of the value of axillary node sampling in addition to sentinel lymph node biopsy in patients with breast cancer" 29 : 526-531, 2003